{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:44:47Z","timestamp":1789706687106,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s11239-019-02029-y","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T16:02:38Z","timestamp":1577980958000},"page":"667-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-3588","authenticated-orcid":false,"given":"Fernanda Salles","family":"Seguro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Lane Cardoso","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane In\u00eas","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellington Fernandes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Nardinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"2029_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0011-5029(70)80012-8","volume":"16","author":"HS Gilbert","year":"1970","unstructured":"Gilbert HS, Dameshek W (1970) The myeloproliferative disorders. Dis Month 16:1\u201352","journal-title":"Dis Month"},{"issue":"7","key":"2029_CR2","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3(7):e270. https:\/\/doi.org\/10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"issue":"10","key":"2029_CR3","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123(10):1552\u20131555","journal-title":"Blood"},{"issue":"7037","key":"2029_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144\u20131148","journal-title":"Nature"},{"issue":"6","key":"2029_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/PPO.0b013e318159467b","volume":"13","author":"A Tefferi","year":"2007","unstructured":"Tefferi A (2007) JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 13(6):366\u2013371","journal-title":"Cancer J"},{"issue":"10","key":"2029_CR6","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544\u20131551","journal-title":"Blood"},{"issue":"7","key":"2029_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7):1299\u20131307","journal-title":"Leukemia"},{"issue":"24","key":"2029_CR8","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"20","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TML, Landgren O, Eloranta S, Derolf \u00c5R et al (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 20(24):2995\u20133001","journal-title":"J Clin Oncol"},{"issue":"4","key":"2029_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL et al (2019) 3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94(4):599\u2013610","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2029_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","volume":"97","author":"PJJ Van Genderen","year":"1997","unstructured":"Van Genderen PJJ, Mulder PGH, Waleboer M, Van De Moesdijk D, Michiels JJ (1997) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 97(1):179\u201384","journal-title":"Br J Haematol"},{"issue":"6","key":"2029_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ejh.12873","volume":"98","author":"K Abdulkarim","year":"2017","unstructured":"Abdulkarim K, Samuelsson J, Johansson P, Andr\u00e9asson B (2017) Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: real-world data from the Swedish MPN registry. Eur J Haematol 98(6):577\u2013583. https:\/\/doi.org\/10.1111\/ejh.12873","journal-title":"Eur J Haematol"},{"issue":"3","key":"2029_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372\u2013380","journal-title":"Haematologica"},{"issue":"1","key":"2029_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-017-0042-7","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2018) Polycythemia vera treatment algorithm. Blood Cancer J 8(1):3","journal-title":"Blood Cancer J"},{"issue":"11","key":"2029_CR14","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A et al (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5(11):e369","journal-title":"Blood Cancer J"},{"issue":"6","key":"2029_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"9","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al (2012) A prognostic model to predict survival in 867 World Health Organization - Defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment. Blood 9(6):1197\u20131201","journal-title":"Blood"},{"issue":"26","key":"2029_CR16","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133","journal-title":"Blood"},{"issue":"6","key":"2029_CR17","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 109(6):2446\u201352","journal-title":"Blood."},{"issue":"8","key":"2029_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Guglielmelli P, Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Ferrer-Mar\u00edn F et al (2016) Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 101(8):926\u2013931","journal-title":"Haematologica"},{"issue":"11","key":"2029_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","volume":"8","author":"V De Stefano","year":"2018","unstructured":"De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G et al (2018) Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J 8(11):112","journal-title":"Blood Cancer J"},{"issue":"2","key":"2029_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114\u2013124","journal-title":"N Engl J Med"},{"key":"2029_CR21","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"2029_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.plabm.2015.12.004","volume":"4","author":"A Didone","year":"2016","unstructured":"Didone A, Nardinelli L, Marchiani M, Ruiz ARL, de Lima Costa AL, Lima IS et al (2016) Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. Pract Lab Med 4:30\u201337","journal-title":"Pract Lab Med"},{"issue":"2","key":"2029_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"issue":"1","key":"2029_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, H\u00e4nel M, Gattermann N et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9(1):18","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2029_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4274\/tjh.2016.0005","volume":"34","author":"N Soyer","year":"2017","unstructured":"Soyer N, Haznedaro\u011flu \u0130C, C\u00f6mert M, \u00c7ekdemir D, Y\u0131lmaz M, \u00dcnal A et al (2017) Multicenter retrospective analysis of Turkish patients with chronic myeloproliferative neoplasms. Turk J Haematol 34(1):27\u201333","journal-title":"Turk J Haematol"},{"key":"2029_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.03.009","author":"A Enblom","year":"2015","unstructured":"Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J et al (2015) High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2015.03.009","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2029_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1160\/th15-04-0326","volume":"115","author":"V De Stefano","year":"2016","unstructured":"De Stefano V, Qi X, Betti S, Rossi E (2016) Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 115(2):240\u2013249","journal-title":"Thromb Haemost"},{"key":"2029_CR28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057\u20131069","journal-title":"Leukemia"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-02029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-02029-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-02029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:31:01Z","timestamp":1609461061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-02029-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-02029-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"2 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest in preparing this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}